The risks of microdosing are significant and multifaceted: Therapeutic inefficacy : Sub-therapeutic doses may fail to achieve meaningful improvements in glycaemic control or weight management, potentially delaying appropriate treatment and allowing disease progression
GLP-1 ,
Hopper I, Gronda E, Hoppe UC, Rundqvist B, Marwick TH, Shetty S, et al
Without attention to fiber, hydration, and meal structure, constipation can persist throughout GLP-1 therapy
29 In terms of the nervous system, GLP-1 receptor (GLP-1R) expression is enriched in central nervous system (CNS) regions, including the hypothalamus, which regulates appetite, and the brainstem, which primarily secretes brain-derived GLP-1, as well as in the peripheral vagus nerve